Comparison of lung deposition of colomycin using the Halolite and the Pari LC Plus nebulisers in patients with cystic fibrosis

Archives of Disease in Childhood

Volumn 88, Issue 8, 2003, Pages 715-718

  Byrne, N M ^a   Keavey, P M ^a   Perry, J D ^a   Gould, F K ^a   Spencer, D A ^a  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; PENTETATE TECHNETIUM TC 99M;

AEROSOL; ANTIBIOTIC THERAPY; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG UPTAKE; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LUNG DEPOSIT; LUNG INFECTION; MEDICAL NEBULIZER; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; COLISTIN; CROSS-OVER STUDIES; CYSTIC FIBROSIS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; OPPORTUNISTIC INFECTIONS; PSEUDOMONAS INFECTIONS; RADIOPHARMACEUTICALS; SPUTUM; TECHNETIUM TC 99M PENTETATE;

EID: 0043033238     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.8.715     Document Type: Article

References (16)

1. Pitcher-Wilmott RW, Levinsky RJ, Gordon I. Pseudomonas infections, allergy, and cystic fibrosis. Arch Dis Child 1982;57:582-6.
2. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillen and gentamycin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;ii:1137-9.
3. Littlewood JM, Miller MG, Ghonheim AT, et al. Nebulised Colomycin for early pseudomonas colonisation in cystic fibrosis [letter]. Lancet 1985;1:865.
4. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1999;338:725-6.
5. Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-604.
6. Mukhopadhyay S, Singh M, Cater JI, et al. Nebulised anti-pseudomonal antibiotic therapy in cystic fibrosis: a meta analysis of benefits and risks. Thorax 1996;51:364-8.
7. Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults in cystic fibrosis. Thorax 1994;49:115-20.
8. Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33.
9. Dyche JA, Medic Aid Ltd, Bognor Regis, UK. Patient compliance with inhaled treatment using a novel aerosol delivery system [abstract]. ERS Congress, Geneva. Eur Respir J 1998;(suppl):94s.
10. Nikander K, Denyer J, Cobos C. Compliance with nebulised budesonide in Spanish children with asthma using adaptive aerosol delivery (AAD) [abstract]. ERS Congress, Geneva. Eur Respir J 1998;(suppl):88s.
11. Denyer J, Dyche T, Nikander K, et al. HaloLite a novel liquid aerosol delivery system. Thorax 1997;52(suppl 6):A83.
12. O'Doherty MJ, Thomas SHL, Gibb D, et al. Lung deposition of nebulised pentamidine in children. Thorax 1993;48:220-6.
13. Devadason SG, Huang T, Walker SL, et al. Lung deposition of rhDNase in children with cystic fibrosis using the HaloLite Adaptive Aerosol Delivery (AAD™) System and Pari LC+ nebuliser. European Cystic Fibrosis Conference, Vienna 2001, Abstract P84.
14. Chua HL, Collis GG, Le Souef PN. Bronchial response to nebulised antibiotics in children with cystic fibrosis. Eur Respir J 1990;3:1114-16.
15. Dodd ME, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52:656-8.
16. Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001;84:432-3.